A Patient with Transverse Colon Cancer Complicated by Cowden Syndrome Administered FOLFOXIRI+ Bevacizumab Therapy
K Takehara, Y Ishizaki, K Nagakari, M Ohuchi… - Case Reports in …, 2023 - karger.com
Cowden syndrome is characterized by several clinical features related to tumorous lesions
primarily consisting of systemic hamartomas. The mutation of a tumor suppressor gene, the …
primarily consisting of systemic hamartomas. The mutation of a tumor suppressor gene, the …
Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
X Wang, W Wu, Z Zheng, P Chi - Frontiers in Oncology, 2021 - frontiersin.org
RAS is the most common mutated gene in colorectal cancer (CRC), and its occurrence is
associated with primary and acquired resistance to anti-epidermal growth factor receptor …
associated with primary and acquired resistance to anti-epidermal growth factor receptor …
[HTML][HTML] Role of circulating free DNA in colorectal cancer
A Matikas, A Voutsina, M Trypaki… - World Journal of …, 2016 - ncbi.nlm.nih.gov
The gradual elucidation of the underlying biology of colorectal cancer has provided new
insights and therapeutic options for patients with metastatic disease which are selected …
insights and therapeutic options for patients with metastatic disease which are selected …
Genotype-or phenotype-targeting anticancer therapies? Lessons from tumor evolutionary biology
AE Escargueil, S Prado, A Dezaire… - Current …, 2016 - ingentaconnect.com
Despite the efficacy of most cancer therapies, drug resistance remains a major problem in
the clinic. The eradication of the entire tumor and the cure of the patient by chemotherapy …
the clinic. The eradication of the entire tumor and the cure of the patient by chemotherapy …
A trial protocol of precision medicine for patients with RAS wild metastatic colorectal cancer using liquid biopsy (RAS-liquid study): a prospective, multicenter …
A Matsuda, T Yamada, T Takahashi… - Journal of the Anus …, 2022 - jstage.jst.go.jp
Background: Anti-epidermal growth factor receptor (EGFR) therapy has been identified to
prolong the survival of metastatic colorectal cancer (mCRC) patients without RAS mutations …
prolong the survival of metastatic colorectal cancer (mCRC) patients without RAS mutations …
Report of two patients in whom comparisons of the somatic mutation profile were useful for the diagnosis of metastatic tumors
K Furukawa, K Hatakeyama, M Terashima, K Fujiya… - Surgical Case …, 2022 - Springer
Background When a patient has multiple tumors in different organs, it is very important to
identify whether the tumors are multiple cancers or metastasis from one tumor in order to …
identify whether the tumors are multiple cancers or metastasis from one tumor in order to …
Management of patients with colorectal liver metastasis in eleven questions and answers
Introduction: Colorectal liver metastasis (CRLM) is the most frequent indication for liver
resection in many centers. Recent improvements in oncology, surgery, interventional …
resection in many centers. Recent improvements in oncology, surgery, interventional …
结直肠癌原发与配对转移肿瘤遗传异质性研究进展
鲁有望, 王昆华 - 遗传, 2017 - chinagene.cn
结直肠癌(colorectal cancer, CRC) 是我国常见的致死性肿瘤类型之一. 根据体细胞突变谱预测
抗EGFR 单抗治疗疗效已成为转移性结直肠癌(metastatic colorectal cancer, mCRC) …
抗EGFR 单抗治疗疗效已成为转移性结直肠癌(metastatic colorectal cancer, mCRC) …
Sequencing of RAS/RAF pathway genes in primary colorectal cancer and matched liver and lung metastases
N Knijn, C van de Water, S van Vliet, J Meijer… - Applied Cancer …, 2019 - Springer
Background Mutations in the RAS/RAF pathway predict resistance to anti-epidermal growth
factor receptor antibodies in colorectal cancer (CRC), and may be targets for future …
factor receptor antibodies in colorectal cancer (CRC), and may be targets for future …
[HTML][HTML] Performance of prognostic models incorporating KRAS mutation status to predict survival after resection of colorectal liver metastases
Abstract Background The Genetic And Morphologic Evaluation (GAME) score and modified
clinical score (m-CS) are two novel prognostic models that incorporate KRAS mutation …
clinical score (m-CS) are two novel prognostic models that incorporate KRAS mutation …